Literature DB >> 8071609

Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study.

E J Schaefer1, S Lamon-Fava, J M Ordovas, S D Cohn, M M Schaefer, W P Castelli, P W Wilson.   

Abstract

A decreased high density lipoprotein (HDL) cholesterol level (< 35 mg/dl) has been shown to be a significant independent risk factor for coronary heart disease (CHD). Moreover, increased HDL cholesterol levels (> or = 60 mg/dl) are associated with a decreased CHD risk. Levels of HDL cholesterol and apoA-I, the major protein constituent of HDL, were measured in plasma from fasting participants in the Framingham Offspring Study (1,584 men and 1,639 women, mean age 49 +/- 10 years). In this population, an HDL cholesterol value < 35 mg/dl was observed in 18.2% of men and 3.8% of women, and these subjects had mean apoA-I levels of 104 and 106 mg/dl, respectively, and triglyceride levels of 234 and 261 mg/dl, respectively. CHD was observed in 14.2% of men and 14.5% of women in this category. An HDL cholesterol level > or = 60 mg/dl was observed in 11.7% of men and 39.3% of women, and these subjects had mean apoA-I levels of 182 and 185 mg/dl, respectively, and mean triglyceride levels of 81 and 75 mg/dl, respectively. CHD was noted in 2.7% of men and 1.9% of women in this category. HDL cholesterol levels were much more strongly related to triglycerides (r = -0.54 in men and -0.47 in women) than was apoA-I (r = -0.26 in men and -0.13 in women). The relationship between plasma HDL cholesterol and triglyceride levels was not linear. In both men and women, triglycerides, body mass index (BMI), and alcohol intake contributed significantly to HDL cholesterol and apoA-I variability.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8071609

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  24 in total

Review 1.  Impact of dyslipidaemia. Lessons from clinical trials.

Authors:  W V Brown
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

2.  Modulation of lipid metabolism by deep-sea water in cultured human liver (HepG2) cells.

Authors:  Shan He; Jiejie Hao; Weibing Peng; Peiju Qiu; Chunxia Li; Huashi Guan
Journal:  Mar Biotechnol (NY)       Date:  2013-09-24       Impact factor: 3.619

Review 3.  HDL cholesterol and cardiovascular outcomes: what is the evidence?

Authors:  Melvyn Rubenfire; Robert D Brook
Journal:  Curr Cardiol Rep       Date:  2013-04       Impact factor: 2.931

Review 4.  Effects of statins on skeletal muscle: a perspective for physical therapists.

Authors:  Stephanie L Di Stasi; Toran D MacLeod; Joshua D Winters; Stuart A Binder-Macleod
Journal:  Phys Ther       Date:  2010-08-05

5.  High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study.

Authors:  Giovanni Zuliani; Stefano Volpato; Alessando Blè; Stefania Bandinelli; Anna Maria Corsi; Fulvio Lauretani; Giuseppe Paolisso; Renato Fellin; Luigi Ferrucci
Journal:  Atherosclerosis       Date:  2006-06-19       Impact factor: 5.162

6.  Evidence for an exaggerated postprandial lipemia in chronic paraplegia.

Authors:  Mark S Nash; Joris DeGroot; Alberto Martinez-Arizala; Armando J Mendez
Journal:  J Spinal Cord Med       Date:  2005       Impact factor: 1.985

Review 7.  Diagnosis and treatment of high density lipoprotein deficiency.

Authors:  Ernst J Schaefer; Pimjai Anthanont; Margaret R Diffenderfer; Eliana Polisecki; Bela F Asztalos
Journal:  Prog Cardiovasc Dis       Date:  2016-08-24       Impact factor: 8.194

8.  Lipoprotein levels and cardiovascular risk in HIV-infected and uninfected Rwandan women.

Authors:  Kathryn Anastos; François Ndamage; Dalian Lu; Mardge H Cohen; Qiuhu Shi; Jason Lazar; Venerand Bigirimana; Eugene Mutimura
Journal:  AIDS Res Ther       Date:  2010-08-26       Impact factor: 2.250

Review 9.  Approach to the patient with extremely low HDL-cholesterol.

Authors:  Daniel J Rader; Emil M deGoma
Journal:  J Clin Endocrinol Metab       Date:  2012-10       Impact factor: 5.958

10.  Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.

Authors:  Evan A Stein; Eli M Roth; James M Rhyne; Tracy Burgess; David Kallend; Jennifer G Robinson
Journal:  Eur Heart J       Date:  2010-01-22       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.